AntriaBio (OTC:ANTB) said today that the first patient was dosed in a Phase I first-in-human trial of its once-weekly basal insulin. The single ascending dose study is designed to test the safety, pharmacokinetics and dynamics of AB101 in patients with Type I diabetes. Get the full story at our sister site, Drug Delivery Business News.
antriabio
AntriaBio raises $13m for injectable, once-weekly insulin
AntriaBio (OTC:ANTB) said today that it closed a $13 million private placement, supported by Aju Pharm, Ildong Pharmaceutical Co. and Medici Investment Co. According to the deal, investors paid $1.00 per share of common stock. Get the full story at our sister site, Drug Delivery Business News.
AntriaBio seeks FDA nod for trial of once-weekly insulin
AntriaBio (OTC:ANTB) said today that it filed an investigational new drug application with the FDA for its once-weekly basal insulin. If the Louisville, Colo.-based company wins approval from the FDA, it plans to launch a Phase I clinical trial of AB101 in patients with Type I diabetes. Get the full story at our sister site, […]